Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 4/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3916264 | 0.76 | MAPT (0.53) | MAPTALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL3914678 | 0.74 | ALDH1A1 (0.58) | MAPTALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL3911289 | 0.72 | FLT3 (0.61) | MAPTALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL3913986 | 0.72 | ALDH1A1 (0.68) | MAPTALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL7455441 | 0.71 | KDM4E (0.68) | MAPTALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL3923547 | 0.71 | ANO1 (0.57) | MAPTALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL2803645 | 0.70 | ALDH1A1 (0.65) | MAPTALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL3915479 | 0.70 | MAPT (0.46) | MAPTALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL11083116 | 0.70 | ALDH1A1 (0.50) | MAPTALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL6037024 | 0.68 | ALDH1A1 (0.68) | MAPTALDH1A1KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298842-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | PATO JANOS | 2009-12-03 | — | — | US | claimed |
| US-20090018149-A1 | 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections | AXXIMA PHARMACEUTICALS AG (DE) | 2009-01-15 | — | — | US | claimed |
| US-20040171603-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | VICHEM CHEMIE KFT (HU) | 2004-09-02 | — | — | US | claimed |
| US-20090298842-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | PATO JANOS | 2009-12-03 | — | — | US | disclosed |
| US-20090018149-A1 | 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections | AXXIMA PHARMACEUTICALS AG (DE) | 2009-01-15 | — | — | US | disclosed |
| EP-1492783-A1 | 4,5,6,7-TRETRAHYDROBENZO(B) THIOPHENE DERIVATIVES AND METHODS FOR MEDICAL INTERVENTION AGAINST MYCROBACTERIAL INFECTIONS | Axxima Pharmaceuticals AG (DE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040171603-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | VICHEM CHEMIE KFT (HU) | 2004-09-02 | — | — | US | disclosed |
| WO-2003084947-A1 | 4,5,6,7-TRETRAHYDROBENZO[B] THIOPHENE DERIVATIVES AND METHODS FOR MEDICAL INTERVENTION AGAINST MYCROBACTERIAL INFECTIONS | AXXIMA PHARMACEUTICALS AG (DE) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298842-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | PKLR, MASTL, BPGM | MAPT 3062/4885ALDH1A1 4718/4885KDM4E 2651/4885 |
| US-20040171603-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | PKLR, PKN1, PKMYT1 | MAPT 2046/4885ALDH1A1 4655/4885KDM4E 2941/4885 |
| US-20090018149-A1 | 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections | STK4, SBK3, STK17B | MAPT 2119/4885ALDH1A1 4146/4885KDM4E 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.